The Market Size Of Bivalent Hpv Vaccine Is Expected To Exceed 100 Billion

According to the research report of securities companies, there are only four HPV vaccine manufacturers in the world, mainly because of the technical difficulty, and the long development cycle and high cost of HPV vaccine.

The number of batches of HPV vaccines issued in my country has increased year by year, but the penetration rate is still low. According to the research report of West China Securities, the penetration rate of domestic HPV vaccination among school-age women is about 5.2%.

In November 2020, the World Health Organization (WHO) launched the "Global Strategy to Accelerate Cervical Cancer Elimination". my country plans to launch pilot projects in 15 cities to promote the application of cervical cancer vaccine, and many places have introduced preferential policies for HPV vaccination of school-age women.

Industry insiders believe that the domestic bivalent HPV vaccine market space is expected to open up.

Guolian Securities estimates that the market demand for women alone exceeds 100 billion yuan. The domestic vaccine production capacity has expanded rapidly and is expected to benefit fully. In addition, domestic and foreign companies are also actively conducting research on male indications.

Based on the good market prospects, many domestic enterprises are actively deploying, and many of them are listed companies.

In addition to the bivalent HPV vaccine, Wantai Bio and Watson Bio have also deployed a nine-valent HPV vaccine. In addition, China Cell's 14-valent HPV vaccine is undergoing clinical phase I/II research; the 15-valent HPV vaccine jointly developed by Chengda Biology and Recreation Guard has recently been approved for clinical use.

The performance of related companies deploying HPV vaccines has been boosted. With the advantages of price and other advantages, Wantai Bio's bivalent HPV vaccine Xin Ke Ning ushered in a rapid increase in volume after its launch.

The annual report shows that in 2021, the company's net profit attributable to the parent company will be 2.021 billion yuan, a year-on-year increase of 198.59%. Regarding the reasons for the rapid growth of performance, the company stated that the bivalent HPV vaccine continued to maintain a boom in production and sales, and revenue and profit grew rapidly.

The brokerage predicts that in 2021, the company's total confirmed sales of bivalent HPV vaccines will be about 10 million. Assuming a net profit rate of 35%, the corresponding net profit will be about 1.2 billion yuan.

As the exclusive agent of Merck's quadrivalent and nine-valent HPV vaccines, Zhifei Bio is expected to account for more than 80% of its HPV vaccine business revenue.